On September 28, 2018, I attended the Living Beyond Breast Cancer Conference that was co-hosted by The Triple Negative Breast Cancer Foundation in Philadelphia. A lot of promising research is still ongoing for Triple Negative Breast Cancer... PARP Inhibitors was FDA approved in October 2018 for BRCA positive metastatic TNBC. Immunotherapy and Antibody-drug conjugates is also emerging in TNBC clinical trials with favorable results in complete response in metastatic Triple Negative Breast Cancer.
My beautiful hotel room view of Philadelphia skyline |
No One Fights Alone! TNBC sisters Sara K. and Melissa |
Hayley Dinerman, Co-founder and President of Triple Negative Breast Cancer Foundation https://tnbcfoundation.org |
Diagnosed with Triple Negative Breast Cancer before the age of 60? |
Promising Immunotherapy research for TNBC still in clinical trials |
The safety of Pembrolizumab Monotherapy has demonstrated as being favorable as a first-line therapy with PD-L1 positive Metastatic Triple Negative Breast Cancer. |
Breast Cancer Oncologist, Reshma L. Mahtani Identifying the different subtypes of Triple Negative Breast Cancer |
PARP Inhibitors as an emerging target for Metastatic TNBC patients that are also BRCA positive of the gene mutation |
Most breast cancer in African women are triple negative |
Who's at higher risk of Triple Negative Breast Cancer? |
Brain metastases is much higher in advanced Triple Negative Breast Cancer than other breast cancer subtypes |
Me and the ladies of the TNBC Foundation Allison Axenrod, Amy Mustica, Melissa Paskvan, Arlene Brothers and Hayley Dinerman |
Fighting for a TNBC targeted therapy breakthrough! |
Pow! |
"Rocky" |
Breast cancer sisters Terlisa Sheppard and Melissa |
#KissThis4MBC |
Melissa and Josh Levin of lymphedivas.com |
TNBC sister, Sara K. showing off her new sleeve just purchased from a vendor, lymphedivas.com |
Cheers! Party-crasher of a cancer fundraiser! |
Triple Negative Breast Cancer sisters Addys S. and Melissa |